Success in this area means ensuring the right therapy reaches the patient in a form that is stable, effective, and ready for ...

Don’t miss the return of the Translational Digital Pathology & AI Summit, uniting 60+ leading biopharma pioneers driving the ...

The Synthetic Human Genome (SynHG) Project, launched on the 25th anniversary of the mapping of the human genome, is being ...

The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

Following a pre-Congress press briefing and data presented onsite at ASCO 2025 itself, pharmaphorum spoke with Dr Victoria ...

The NNF – a philanthropic non-profit organisation that owns a controlling stake in Danish drugmaker Novo Nordisk – has been ...

The Obesity Drug Development Summit Europe is your perfect platform to be in a prime position to be at the forefront of this ...

The Neuropsychiatric Drug Development Summit returns for its eighth year as the industry’s flagship forum capturing ...

At BIO 2025, pharmaphorum Editor in Chief spoke with Hanadie Yousef, CEO of Juvena Therapeutics, a biotech focused on discovering and developing tissue-restorative biologics for chronic age-related ...

To close the innovation-access gap, there is a desperate need for an infrastructure rooted in trust. That means complementing human care with tools powered by AI that offer accessible diagnostics, ...

An alternative to epinephrine autoinjectors that can be delivered by a nasal spray has been launched in Germany, its first ...

The STAAR trial showed that a one-shot dose of ST-920 – now known as isaralgagene civaparvovec – was able to improve kidney ...